Drugs, genes and the blues: Pharmacogenetics of the antidepressant response from mouse to man

Pharmacology Biochemistry and Behavior

Volumn 123, Issue , 2014, Pages 55-76

  O'Leary, Olivia F ^a,b   O'Brien, Fionn E ^a,b   O'Connor, Richard M ^a   Cryan, John F ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Animal model; Antidepressant; Depression; Personalised medicine; Pharmacogenetics; Treatment resistant depression

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450; DOPAMINE; DOPAMINE TRANSPORTER; GLUTAMATE RECEPTOR; MICRORNA; MULTIDRUG RESISTANCE PROTEIN 1; NORADRENALIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 2; VESICULAR MONOAMINE TRANSPORTER 2;

DEPRESSION; DRUG RESPONSE; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; MOUSE; NONHUMAN; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL;

ANIMALIA; POLYOMMATINAE;

ANIMALS; ANTIDEPRESSIVE AGENTS; HUMANS; MICE; PHARMACOGENETICS;

EID: 84905239159     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2013.10.015     Document Type: Review

References (419)

1. M. Adachi, M. Barrot, A.E. Autry, D. Theobald, and L.M. Monteggia Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy Biol Psychiatry 63 2008 642 649 (Pubitemid 351329281)
2. T. Aid, A. Kazantseva, M. Piirsoo, K. Palm, and T. Timmusk Mouse and rat BDNF gene structure and expression revisited J Neurosci Res 85 2007 525 535
3. P.R. Albert, and S. Lemonde 5-HT1A receptors, gene repression, and depression: guilt by association Neuroscientist 10 2004 575 593 (Pubitemid 39546399)
4. G.S. Alexopoulos, C.E. Glatt, M.J. Hoptman, D. Kanellopoulos, C.F. Murphy, and R.E. Kelly Jr. et al. BDNF val66met polymorphism, white matter abnormalities and remission of geriatric depression J Affect Disord 125 2010 262 268
5. C.L. Alfaro, Y.W. Lam, J. Simpson, and L. Ereshefsky CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations J Clin Pharmacol 40 2000 58 66
6. A. Alkelai, L. Greenbaum, A. Rigbi, K. Kanyas, and B. Lerer Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients Psychopharmacology (Berl) 206 2009 491 499
7. S.V. Ambudkar, C. Kimchi-Sarfaty, Z.E. Sauna, and M.M. Gottesman P-glycoprotein: from genomics to mechanism Oncogene 22 2003 7468 7485 (Pubitemid 37487170)
8. M.S. Ansorge, M. Zhou, A. Lira, R. Hen, and J.A. Gingrich Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice Science 306 2004 879 881 (Pubitemid 39446998)
9. M.S. Ansorge, E. Morelli, and J.A. Gingrich Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice J Neurosci 28 2008 199 207
10. B. Arias, R. Catalan, C. Gasto, B. Gutierrez, and L. Fananas Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram J Psychopharmacol 19 2005 166 172 (Pubitemid 40577221)
11. B. Arias, A. Serretti, C. Lorenzi, C. Gasto, R. Catalan, and L. Fananas Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin J Affect Disord 90 2006 251 256 (Pubitemid 43185979)
12. B. Arias, C. Fabbri, F. Gressier, A. Serretti, M. Mitjans, and C. Gasto et al. TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression Neuropsychobiology 67 2013 41 47
13. A.E. Autry, M. Adachi, E. Nosyreva, E.S. Na, M.F. Los, and P.F. Cheng et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses Nature 475 2011 91 95
14. S. Baltes, A.M. Gastens, M. Fedrowitz, H. Potschka, V. Kaever, and W. Loscher Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein Neuropharmacology 52 2007 333 346 (Pubitemid 46123353)
15. L. Bao, M. Zhou, L. Wu, L. Lu, D. Goldowitz, and R.W. Williams et al. PolymiRTS Database: linking polymorphisms in microRNA target sites with complex traits Nucleic Acids Res 35 2007 D51 D54
16. N.M. Barnes, and T. Sharp A review of central 5-HT receptors and their function Neuropharmacology 38 1999 1083 1152 (Pubitemid 29292403)
17. A. Baudry, S. Mouillet-Richard, B. Schneider, J.M. Launay, and O. Kellermann miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants Science 329 2010 1537 1541
18. B.T. Baune, C. Hohoff, K. Berger, A. Neumann, S. Mortensen, and T. Roehrs et al. Association of the COMT val158met variant with antidepressant treatment response in major depression Neuropsychopharmacology 33 2008 924 932 (Pubitemid 351252697)
19. B.T. Baune, C. Hohoff, T. Roehrs, J. Deckert, V. Arolt, and K. Domschke Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression? Neurosci Lett 436 2008 111 115
20. J.M. Beaulieu, X. Zhang, R.M. Rodriguiz, T.D. Sotnikova, M.J. Cools, W.C. Wetsel, R.R. Gainetdinov, and M.G. Caron Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency Proceedings of the National Academy of Sciences of the United States of America. 105 2008 1333 1338 (Pubitemid 351397053)
21. F. Benedetti, C. Colombo, A. Serretti, C. Lorenzi, A. Pontiggia, and B. Barbini et al. Antidepressant effects of light therapy combined with sleep deprivation are influenced by a functional polymorphism within the promoter of the serotonin transporter gene Biol Psychiatry 54 2003 687 692 (Pubitemid 37281384)
22. F. Benedetti, C. Colombo, A. Pirovano, E. Marino, and E. Smeraldi The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting Psychopharmacology (Berl) 203 2009 155 160
23. F. Benedetti, B. Barbini, A. Bernasconi, M.C. Fulgosi, S. Dallaspezia, and C. Gavinelli et al. Acute antidepressant response to sleep deprivation combined with light therapy is influenced by the catechol-O-methyltransferase Val(108/158)Met polymorphism J Affect Disord 121 2010 68 72
24. S. Bhatnagar, N. Nowak, L. Babich, and L. Bok Deletion of the 5-HT3 receptor differentially affects behavior of males and females in the Porsolt forced swim and defensive withdrawal tests Behav Brain Res 153 2004 527 535 (Pubitemid 38953130)
25. E.B. Binder The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders Psychoneuroendocrinology 34 Suppl. 1 2009 S186 S195
26. E.B. Binder, D. Salyakina, P. Lichtner, G.M. Wochnik, M. Ising, and B. Putz et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment Nat Genet 36 2004 1319 1325 (Pubitemid 39577942)
27. R.D. Blakely, L.J. Defelice, and A. Galli Biogenic amine neurotransmitter transporters: just when you thought you knew them Physiology (Bethesda) 20 2005 225 231 (Pubitemid 41215196)
28. J. Bockaert, L. Fagni, and A. Dumuis 5-HT4 receptors: an update H.G. Baumgarten, M. Gothert, Serotoninergic neurons and 5-HT receptors in the CNS 1997 Springer Berlin 239 268
29. A. Bortolozzi, M. Amargos-Bosch, M. Toth, F. Artigas, and A. Adell In vivo efflux of serotonin in the dorsal raphe nucleus of 5-HT1A receptor knockout mice J Neurochem 88 2004 1373 1379 (Pubitemid 38366912)
30. N. Bozina, A.M. Peles, M. Sagud, H. Bilusic, and M. Jakovljevic Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder World J Biol Psychiatry 2007 1 8
31. N. Bozina, A.M. Peles, M. Sagud, H. Bilusic, and M. Jakovljevic Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder World J Biol Psychiatry 9 2008 190 197
32. G. Breen, B.T. Webb, A.W. Butler, E.J. van den Oord, F. Tozzi, and N. Craddock et al. A genome-wide significant linkage for severe depression on chromosome 3: the depression network study Am J Psychiatry 168 2011 840 847
33. B. Breitenstein, S. Scheuer, H. Pfister, M. Uhr, S. Lucae, and F. Holsboer et al. The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study CNS Spectr 2013 1 11
34. B.H. Brummett, S.H. Boyle, I.C. Siegler, C.M. Kuhn, A. Ashley-Koch, and C.R. Jonassaint et al. Effects of environmental stress and gender on associations among symptoms of depression and the serotonin transporter gene linked polymorphic region (5-HTTLPR) Behav Genet 38 2008 34 43 (Pubitemid 351164912)
35. C. Bundgaard, C.J. Jensen, and M. Garmer Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice Drug Metab Dispos 40 2012 461 466
36. K.S. Button, J.P. Ioannidis, C. Mokrysz, B.A. Nosek, J. Flint, and E.S. Robinson et al. Power failure: why small sample size undermines the reliability of neuroscience Nat Rev Neurosci 14 2013 365 376
37. G.V. Carr, L.E. Schechter, and I. Lucki Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats Psychopharmacology (Berl) 213 2011 499 507
38. O. Cases, I. Seif, J. Grimsby, P. Gaspar, K. Chen, and S. Pournin et al. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA Science 268 1995 1763 1766
39. A. Caspi, K. Sugden, T.E. Moffitt, A. Taylor, I.W. Craig, and H. Harrington et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene Science 301 2003 386 389 (Pubitemid 36877077)
40. J.S. Catches, J. Xu, and A. Contractor Genetic ablation of the GluK4 kainate receptor subunit causes anxiolytic and antidepressant-like behavior in mice Behav Brain Res 228 2012 406 414
41. L. Cervo, A. Canetta, E. Calcagno, S. Burbassi, G. Sacchetti, and S. Caccia et al. Genotype-dependent activity of tryptophan hydroxylase-2 determines the response to citalopram in a mouse model of depression J Neurosci 25 2005 8165 8172 (Pubitemid 41292111)
42. Z.Y. Chen, D. Jing, K.G. Bath, A. Ieraci, T. Khan, and C.J. Siao et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior Science 314 2006 140 143 (Pubitemid 44547760)
43. M.H. Chi, H.H. Chang, S.Y. Lee, I.H. Lee, P.W. Gean, and Y.K. Yang et al. Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder J Affect Disord 126 2010 430 435
44. M.J. Choi, R.H. Kang, B.J. Ham, H.Y. Jeong, and M.S. Lee Serotonin receptor 2A gene polymorphism (- 1438A/G) and short-term treatment response to citalopram Neuropsychobiology 52 2005 155 162
45. M.J. Choi, R.H. Kang, S.W. Lim, K.S. Oh, and M.S. Lee Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder Brain Res 1118 2006 176 182
46. G. Clarke, S.M. O'Mahony, J.F. Cryan, and T.G. Dinan Verapamil in treatment resistant depression: a role for the P-glycoprotein transporter? Hum Psychopharmacol 24 2009 217 223
47. D.A. Collier, G. Stober, T. Li, A. Heils, M. Catalano, and D. Di Bella et al. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders Mol Psychiatry 1 1996 453 460 (Pubitemid 126439785)
48. V. Compan, M. Zhou, R. Grailhe, R.A. Gazzara, R. Martin, and J. Gingrich et al. Attenuated response to stress and novelty and hypersensitivity to seizures in 5-HT4 receptor knock-out mice J Neurosci 24 2004 412 419 (Pubitemid 38112372)
49. P.J. Conn Physiological roles and therapeutic potential of metabotropic glutamate receptors Ann N Y Acad Sci. 1003 2003 12 21 (Pubitemid 38083042)
50. C. Cordoncardo, J.P. O'Brien, D. Casals, L. Rittmangrauer, J.L. Biedler, and M.R. Melamed et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial-cells at blood-brain barrier sites Proc Natl Acad Sci U S A 86 1989 695 698 (Pubitemid 19037807)
51. N. Craddock, M.J. Owen, and M.C. O'Donovan The catechol-O-methyl transferase (COMT) gene as a candidate for psychiatric phenotypes: evidence and lessons Mol Psychiatry 11 2006 446 458
52. T.I. Cremers, M. Giorgetti, F.J. Bosker, S. Hogg, J. Arnt, and A. Mork et al. Inactivation of 5-HT(2C) receptors potentiates consequences of serotonin reuptake blockade Neuropsychopharmacology 29 2004 1782 1789 (Pubitemid 39336789)
53. J.J. Crowley, E.S. Brodkin, J.A. Blendy, W.H. Berrettini, and I. Lucki Pharmacogenomic evaluation of the antidepressant citalopram in the mouse tail suspension test Neuropsychopharmacology 31 2006 2433 2442 (Pubitemid 44607061)
54. J.J. Crowley, R.H. Lipsky, I. Lucki, and W.H. Berrettini Variation in the genes encoding vesicular monoamine transporter 2 and beta-1 adrenergic receptor and antidepressant treatment outcome Psychiatr Genet 18 2008 248 251
55. J.F. Cryan, and A. Holmes The ascent of mouse: advances in modelling human depression and anxiety Nat Rev Drug Discov 4 2005 775 790 (Pubitemid 43090498)
56. J.F. Cryan, and K. Kaupmann Don't worry 'B' happy!: a role for GABA(B) receptors in anxiety and depression Trends Pharmacol Sci 26 2005 36 43 (Pubitemid 40052708)
57. J.F. Cryan, and B.E. Leonard 5-HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response Hum Psychopharmacol 15 2000 113 135 (Pubitemid 30199285)
58. J.F. Cryan, and I. Lucki 5-HT4 receptors do not mediate the antidepressant-like behavioral effects of fluoxetine in a modified forced swim test Eur J Pharmacol 409 2000 295 299
59. J.F. Cryan, and I. Lucki Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine(2C) receptors J Pharmacol Exp Ther 295 2000 1120 1126
60. J.F. Cryan, A. Dalvi, S.H. Jin, B.R. Hirsch, I. Lucki, and S.A. Thomas Use of dopamine-beta-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs J Pharmacol Exp Ther 298 2001 651 657 (Pubitemid 32673416)
61. J.F. Cryan, O.F. O'Leary, S.H. Jin, J.C. Friedland, M. Ouyang, and B.R. Hirsch et al. Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors Proc Natl Acad Sci U S A 101 2004 8186 8191 (Pubitemid 38698075)
62. J.F. Cryan, C. Mombereau, and A. Vassout The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice Neurosci Biobehav Rev 29 2005 571 625 (Pubitemid 40755457)
63. J.F. Cubells, L.H. Price, B.S. Meyers, G.M. Anderson, C.P. Zabetian, and G.S. Alexopoulos et al. Genotype-controlled analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major depression Biol Psychiatry 51 2002 358 364 (Pubitemid 34251172)
64. C. Cusin, A. Serretti, R. Zanardi, E. Lattuada, D. Rossini, and R. Lilli et al. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity Int J Neuropsychopharmacol 5 2002 27 35 (Pubitemid 34241064)
65. O.L. de Klerk, A.T.M. Willemsen, M. Roosink, A.L. Bartels, N.H. Hendrikse, and F.J. Bosker et al. Locally increased P-glycoprotein function in major depression: a PET study with [C-11]verapamil as a probe for P-glycoprotein function in the blood-brain barrier Int J Neuropsychopharmacol 12 2009 895 904
66. O.L. de Klerk, I.M. Nolte, P.M. Bet, F.J. Bosker, H. Snieder, and J.A. den Boer et al. ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder Pharmacogenomics J 13 4 2013 349 353
67. J. de Leon, S.C. Armstrong, and K.L. Cozza Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19 Psychosomatics 47 2006 75 85 (Pubitemid 43017126)
68. A. de Vos, J. van der Weide, and H.M. Loovers Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients Pharmacogenomics J 11 2011 359 367
69. P.L. Delgado, L.H. Price, H.L. Miller, R.M. Salomon, J. Licinio, and J.H. Krystal et al. Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression Psychopharmacol Bull 27 1991 321 330
70. R. Delorme, C.M. Durand, C. Betancur, M. Wagner, S. Ruhrmann, and H.J. Grabe et al. No human tryptophan hydroxylase-2 gene R441H mutation in a large cohort of psychiatric patients and control subjects Biol Psychiatry 60 2006 202 203
71. I. D'Empaire, C.J. Guico-Pabia, and S.H. Preskorn Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant? J Psychiatr Pract 17 2011 330 339
72. S.L. Diaz, S. Doly, N. Narboux-Neme, S. Fernandez, P. Mazot, and S.M. Banas et al. 5-HT(2B) receptors are required for serotonin-selective antidepressant actions Mol Psychiatry 17 2012 154 163
73. I. Dincheva, C.E. Glatt, and F.S. Lee Impact of the BDNF Val66Met polymorphism on cognition: implications for behavioral genetics Neuroscientist 18 2012 439 451
74. O. Dogan, N. Yuksel, M.A. Ergun, A. Yilmaz, M.N. Ilhan, and H.E. Karslioglu et al. Serotonin transporter gene polymorphisms and sertraline response in major depression patients Genet Test 12 2008 225 231 (Pubitemid 351860438)
75. S. Doly, E. Valjent, V. Setola, J. Callebert, D. Herve, and J.M. Launay et al. Serotonin 5-HT2B receptors are required for 3,4- methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro J Neurosci 28 2008 2933 2940 (Pubitemid 351398883)
76. K. Domschke, C. Hohoff, L.S. Mortensen, T. Roehrs, J. Deckert, and V. Arolt et al. Monoamine oxidase A variant influences antidepressant treatment response in female patients with major depression Prog Neuropsychopharmacol Biol Psychiatry 32 2008 224 228
77. K. Domschke, B. Lawford, G. Laje, K. Berger, R. Young, and P. Morris et al. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response Int J Neuropsychopharmacol 13 2010 93 101
78. C. Dong, M.L. Wong, and J. Licinio Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans Mol Psychiatry 14 2009 1105 1118
79. A. Doran, R.S. Obach, B.J. Smith, N.A. Hosea, S. Becker, and E. Callegari et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model Drug Metab Dispos 33 2005 165 174 (Pubitemid 40023528)
80. A. Drago, C. Crisafulli, and A. Serretti The genetics of antipsychotic induced tremors: a genome-wide pathway analysis on the STEP-BD SCP sample Am J Med Genet B Neuropsychiatr Genet 156B 2011 975 986
81. R.S. Duman, and L.M. Monteggia A neurotrophic model for stress-related mood disorders Biol Psychiatry 59 2006 1116 1127
82. L.K. Durham, S.M. Webb, P.M. Milos, C.M. Clary, and A.B. Seymour The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder Psychopharmacology (Berl) 174 2004 525 529 (Pubitemid 39119341)
83. L.P. Dwoskin, A.S. Rauhut, K.A. King-Pospisil, and M.T. Bardo Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent CNS Drug Rev 12 2006 178 207 (Pubitemid 46047787)
84. M. Dziedzicka-Wasylewska, A. Faron-Gorecka, M. Kusmider, E. Drozdowska, Z. Rogoz, and J. Siwanowicz et al. Effect of antidepressant drugs in mice lacking the norepinephrine transporter Neuropsychopharmacology 31 2006 2424 2432 (Pubitemid 44607060)
85. M. Eckert, B. Egenberger, F. Doring, and E. Wischmeyer TREK-1 isoforms generated by alternative translation initiation display different susceptibility to the antidepressant fluoxetine Neuropharmacology 61 2011 918 923
86. M.F. Egan, M. Kojima, J.H. Callicott, T.E. Goldberg, B.S. Kolachana, and A. Bertolino et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function Cell 112 2003 257 269 (Pubitemid 36144114)
87. T.B. Ejsing, and K. Linnet Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier Hum Psychopharmacol 20 2005 149 153 (Pubitemid 40372491)
88. T.B. Ejsing, J. Hasselstrom, and K. Linnet The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites Drug Metabol Drug Interact 21 2006 139 162 (Pubitemid 43971436)
89. K.A. Ellsworth, I. Moon, B.W. Eckloff, B.L. Fridley, G.D. Jenkins, and A. Batzler et al. FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder Pharmacogenet Genomics 23 2013 156 166
90. A. Fekadu, S.C. Wooderson, K. Markopoulo, C. Donaldson, A. Papadopoulos, and A.J. Cleare What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies J Affect Disord 116 2009 4 11
91. B. Feng, J.B. Mills, R.E. Davidson, R.J. Mireles, J.S. Janiszewski, and M.D. Troutman et al. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system Drug Metab Dispos 36 2008 268 275 (Pubitemid 351185738)
92. W. Filipowicz, S.N. Bhattacharyya, and N. Sonenberg Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9 2008 102 114
93. C.E. Fiskerstrand, E.A. Lovejoy, and J.P. Quinn An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells FEBS Lett 458 1999 171 174 (Pubitemid 29428177)
94. J.S. Fowler, N. Alia-Klein, A. Kriplani, J. Logan, B. Williams, and W. Zhu et al. Evidence that brain MAO A activity does not correspond to MAO A genotype in healthy male subjects Biol Psychiatry 62 2007 355 358 (Pubitemid 47444275)
95. S. Fudio, A.M. Borobia, E. Pinana, E. Ramirez, B. Tabares, and P. Guerra et al. Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram Eur J Pharmacol 626 2010 200 204
96. M. Fukui, R.M. Rodriguiz, J. Zhou, S.X. Jiang, L.E. Phillips, and M.G. Caron et al. Vmat2 heterozygous mutant mice display a depressive-like phenotype J Neurosci 27 2007 10520 10529 (Pubitemid 47502010)
97. N. Fukui, Y. Suzuki, K. Sawamura, T. Sugai, J. Watanabe, and Y. Inoue et al. Dose-dependent effects of the 3435 C > T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients Ther Drug Monit 29 2007 185 189 (Pubitemid 46716184)
98. A.M. Gardier, D.J. David, G. Jego, C. Przybylski, C. Jacquot, and S. Durier et al. Effects of chronic paroxetine treatment on dialysate serotonin in 5-HT1B receptor knockout mice J Neurochem 86 2003 13 24 (Pubitemid 36753841)
99. B. Geller, T.B. Cooper, H.G. McCombs, D. Graham, and J. Wells Double-blind, placebo-controlled study of nortriptyline in depressed children using a "fixed plasma level" design Psychopharmacol Bull 25 1989 101 108 (Pubitemid 19179170)
100. B. Geller, T.B. Cooper, D.L. Graham, F.A. Marsteller, and D.M. Bryant Double-blind placebo-controlled study of nortriptyline in depressed adolescents using a "fixed plasma level" design Psychopharmacol Bull 26 1990 85 90 (Pubitemid 20322251)
101. GENDEP Investigators, MARS Investigators, and STAR*D Investigators Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies Am J Psychiatry 170 2013 207 217
102. M. Gex-Fabry, C.B. Eap, B. Oneda, N. Gervasoni, J.M. Aubry, and G. Bondolfi et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response Ther Drug Monit 30 2008 474 482
103. C.E. Glatt, E. Carlson, T.R. Taylor, N. Risch, V.I. Reus, and C.A. Schaefer Response to Zhang et al. (2005): loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression Neuron 45 2005 11 16 [Neuron. 2005;48:704-5; author reply 5-6]
104. D.G. Grahame-Smith Tryptophan hydroxylation in brain Biochem Biophys Res Commun 16 1964 586 592
105. M. Gratacos, V. Soria, M. Urretavizcaya, J.R. Gonzalez, J.M. Crespo, and M. Bayes et al. A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders Pharmacogenomics J 8 2008 101 112 (Pubitemid 351411546)
106. M.T. Grauer, and M. Uhr P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline J Psychopharmacol 18 2004 66 74 (Pubitemid 38623096)
107. E. Gudayol-Ferre, I. Herrera-Guzman, B. Camarena, C. Cortes-Penagos, J.E. Herrera-Abarca, and P. Martinez-Medina et al. The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder J Affect Disord 127 2010 343 351
108. G. Guidotti, F. Calabrese, C. Anacker, G. Racagni, C.M. Pariante, and M.A. Riva Glucocorticoid receptor and FKBP5 expression is altered following exposure to chronic stress: modulation by antidepressant treatment Neuropsychopharmacology 38 2013 616 627
109. J.P. Guilloux, D.J. David, B.P. Guiard, F. Chenu, C. Reperant, and M. Toth et al. Blockade of 5-HT1A receptors by (+/-)-pindolol potentiates cortical 5-HT outflow, but not antidepressant-like activity of paroxetine: microdialysis and behavioral approaches in 5-HT1A receptor knockout mice Neuropsychopharmacology 31 2006 2162 2172 (Pubitemid 44413193)
110. I. Gurevich, H. Tamir, V. Arango, A.J. Dwork, J.J. Mann, and C. Schmauss Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims Neuron 34 2002 349 356 (Pubitemid 34465494)
111. B.J. Ham, B.C. Lee, J.W. Paik, R.H. Kang, M.J. Choi, and I.G. Choi et al. Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population Prog Neuropsychopharmacol Biol Psychiatry 31 2007 104 107
112. S.P. Hamilton A new lead from genetic studies in depressed siblings: assessing studies of chromosome 3 Am J Psychiatry 168 2011 783 789
113. M. He, E. Sibille, D. Benjamin, M. Toth, and T. Shippenberg Differential effects of 5-HT1A receptor deletion upon basal and fluoxetine-evoked 5-HT concentrations as revealed by in vivo microdialysis Brain Res 902 2001 11 17 (Pubitemid 32499270)
114. A. Heils, A. Teufel, S. Petri, G. Stober, P. Riederer, and D. Bengel et al. Allelic variation of human serotonin transporter gene expression J Neurochem 66 1996 2621 2624 (Pubitemid 26159101)
115. K. Hek, A. Demirkan, J. Lahti, A. Terracciano, A. Teumer, and M.C. Cornelis et al. A genome-wide association study of depressive symptoms Biol Psychiatry 73 2013 667 678
116. G.R. Heninger, P.L. Delgado, and D.S. Charney The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans Pharmacopsychiatry 29 1996 2 11 (Pubitemid 26071332)
117. S. Henningsson, K. Annerbrink, M. Olsson, C. Allgulander, S. Andersch, and I. Sjodin et al. Absence of the Arg441His polymorphism in the tryptophan hydroxylase 2 gene in adults with anxiety disorders and depression Am J Med Genet B Neuropsychiatr Genet 144B 2007 816 817 (Pubitemid 47417212)
118. S. Henningsson, J. Borg, J. Lundberg, J. Bah, M. Lindstrom, and E. Ryding et al. Genetic variation in brain-derived neurotrophic factor is associated with serotonin transporter but not serotonin-1A receptor availability in men Biol Psychiatry 66 2009 477 485
119. C. Hess, A. Reif, A. Strobel, A. Boreatti-Hummer, M. Heine, and K.P. Lesch et al. A functional dopamine-beta-hydroxylase gene promoter polymorphism is associated with impulsive personality styles, but not with affective disorders J Neural Transm 116 2009 121 130
120. C. Heurteaux, G. Lucas, N. Guy, M. El Yacoubi, S. Thummler, and X.D. Peng et al. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype Nat Neurosci 9 2006 1134 1141 (Pubitemid 44306306)
121. A. Holmes, R.J. Yang, D.L. Murphy, and J.N. Crawley Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter Neuropsychopharmacology 27 2002 914 923 (Pubitemid 35447628)
122. C.J. Hong, T.J. Chen, Y.W. Yu, and S.J. Tsai Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder Pharmacogenomics J 6 2006 27 33 (Pubitemid 43118308)
123. S. Horstmann, and E.B. Binder Pharmacogenomics of antidepressant drugs Pharmacol Ther 124 2009 57 73
124. S. Horstmann, and E.B. Binder Glucocorticoids as predictors of treatment response in depression Harv Rev Psychiatry 19 2011 125 143
125. S. Horstmann, S. Lucae, A. Menke, J.M. Hennings, M. Ising, and D. Roeske et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment Neuropsychopharmacology 35 2010 727 740
126. D. Hoyer, J.P. Hannon, and G.R. Martin Molecular, pharmacological and functional diversity of 5-HT receptors Pharmacol Biochem Behav 71 2002 533 554 (Pubitemid 34219205)
127. X.Z. Hu, R.H. Lipsky, G. Zhu, L.A. Akhtar, J. Taubman, and B.D. Greenberg et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder Am J Hum Genet 78 2006 815 826
128. X.Z. Hu, A.J. Rush, D. Charney, A.F. Wilson, A.J. Sorant, and G.J. Papanicolaou et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression Arch Gen Psychiatry 64 2007 783 792 (Pubitemid 47026374)
129. M. Huang, J. Ichiwaka, Z. Li, J. Dai, and H.Y. Meltzer Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex Psychopharmacology (Berl) 185 2006 274 281
130. P. Huezo-Diaz, R. Uher, R. Smith, M. Rietschel, N. Henigsberg, and A. Marusic et al. Moderation of antidepressant response by the serotonin transporter gene Br J Psychiatry 195 2009 30 38
131. Y. Ibarguen-Vargas, A. Surget, P. Vourc'h, S. Leman, C.R. Andres, and A.M. Gardier et al. Deficit in BDNF does not increase vulnerability to stress but dampens antidepressant-like effects in the unpredictable chronic mild stress Behav Brain Res 202 2009 245 251
132. A. Illi, E. Setala-Soikkeli, M. Viikki, O. Poutanen, H. Huhtala, and N. Mononen et al. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression Neuroreport 20 2009 1125 1128
133. A. Illi, E. Setala-Soikkeli, O. Kampman, M. Viikki, T. Nuolivirta, and O. Poutanen et al. Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder Psychiatry Res 176 2010 85 87
134. K. Ito, K. Yoshida, K. Sato, H. Takahashi, M. Kamata, and H. Higuchi et al. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine Psychiatry Res 111 2002 235 239
135. D.G. Janssen, R.N. Caniato, J.C. Verster, and B.T. Baune A psychoneuroimmunological review on cytokines involved in antidepressant treatment response Hum Psychopharmacol 25 2010 201 215
136. A. Jean, G. Conductier, C. Manrique, C. Bouras, P. Berta, and R. Hen et al. Anorexia induced by activation of serotonin 5-HT4 receptors is mediated by increases in CART in the nucleus accumbens Proc Natl Acad Sci U S A 104 2007 16335 16340 (Pubitemid 350099405)
137. J. Jiao, A.M. Nitzke, D.G. Doukas, M.P. Seiglie, and S.C. Dulawa Antidepressant response to chronic citalopram treatment in eight inbred mouse strains Psychopharmacology (Berl) 213 2011 509 520
138. Y. Jin, B.G. Pollock, E. Frank, G.B. Cassano, P. Rucci, and D.J. Muller et al. Effect of age, weight, and CYP2C19 genotype on escitalopram exposure J Clin Pharmacol 50 2010 62 72
139. M.D. Jones, and I. Lucki Sex differences in the regulation of serotonergic transmission and behavior in 5-HT receptor knockout mice Neuropsychopharmacology 30 2005 1039 1047 (Pubitemid 40720961)
140. E.G. Jonsson, D. Goldman, G. Spurlock, J.P. Gustavsson, D.A. Nielsen, and M. Linnoila et al. Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers Eur Arch Psychiatry Clin Neurosci 247 1997 297 302 (Pubitemid 28010679)
141. P.R. Joyce, R.T. Mulder, S.E. Luty, J.M. McKenzie, A.L. Miller, and G.R. Rogers et al. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline Int J Neuropsychopharmacol 6 2003 339 346 (Pubitemid 38146251)
142. A.V. Kalueff, P.S. Gallagher, and D.L. Murphy Are serotonin transporter knockout mice 'depressed'?: Hypoactivity but no anhedonia Neuroreport 17 2006 1347 1351 (Pubitemid 44337080)
143. R.H. Kang, M.J. Choi, J.W. Paik, S.W. Hahn, and M.S. Lee Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression Int J Psychiatry Med 37 2007 315 329
144. L. Karlsson, U. Schmitt, M. Josefsson, B. Carlsson, J. Ahlner, and F. Bengtsson et al. Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein Eur Neuropsychopharmacol 20 2010 632 640
145. L. Karlsson, C. Hiemke, B. Carlsson, M. Josefsson, J. Ahlner, and F. Bengtsson et al. Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model Psychopharmacology (Berl) 215 2011 367 377
146. L. Karlsson, B. Carlsson, C. Hiemke, J. Ahlner, F. Bengtsson, and U. Schmitt et al. Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment Eur Neuropsychopharmacol 2013 10.1016/j.euroneuro.2013.01.003 (in press)
147. M. Kato, and A. Serretti Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder Mol Psychiatry 15 2010 473 500
148. M. Kato, T. Fukuda, M. Wakeno, K. Fukuda, G. Okugawa, and Y. Ikenaga et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients Neuropsychobiology 53 2006 186 195 (Pubitemid 44252779)
149. M. Kato, M. Wakeno, G. Okugawa, T. Fukuda, J. Azuma, and T. Kinoshita et al. No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression Neuropsychobiology 56 2007 167 171 (Pubitemid 351567532)
150. M. Kato, T. Fukuda, A. Serretti, M. Wakeno, G. Okugawa, and Y. Ikenaga et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder Prog Neuropsychopharmacol Biol Psychiatry 32 2008 398 404 (Pubitemid 351178955)
151. M. Kato, T. Fukuda, M. Wakeno, G. Okugawa, Y. Takekita, and S. Watanabe et al. Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder Am J Med Genet B Neuropsychiatr Genet 150B 2009 115 123
152. M. Katoh, N. Suzuyama, T. Takeuchi, S. Yoshitomi, S. Asahi, and T. Yokoi Kinetic analyses for species differences in P-glycoprotein-mediated drug transport J Pharm Sci 95 2006 2673 2683 (Pubitemid 46093174)
153. C. Kawanishi, S. Lundgren, H. Agren, and L. Bertilsson Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study Eur J Clin Pharmacol 59 2004 803 807 (Pubitemid 38221657)
154. R. Keers, R. Uher, P. Huezo-Diaz, R. Smith, S. Jaffee, and M. Rietschel et al. Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project Pharmacogenomics J 11 2011 138 145
155. K.S. Kendler What psychiatric genetics has taught us about the nature of psychiatric illness and what is left to learn Mol Psychiatry 18 10 2013 1058 1066
156. K.S. Kendler, J.W. Kuhn, J. Vittum, C.A. Prescott, and B. Riley The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication Arch Gen Psychiatry 62 2005 529 535 (Pubitemid 40628882)
157. R.C. Kessler, K.A. McGonagle, M. Swartz, D.G. Blazer, and C.B. Nelson Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence J Affect Disord 29 1993 85 96 (Pubitemid 23334116)
158. R.C. Kessler, P. Berglund, O. Demler, R. Jin, D. Koretz, and K.R. Merikangas et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) JAMA 289 2003 3095 3105 (Pubitemid 37432885)
159. H. Kim, S.W. Lim, S. Kim, J.W. Kim, Y.H. Chang, and B.J. Carroll et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression JAMA 296 2006 1609 1618 (Pubitemid 44511608)
160. J. Kirchheiner, G. Muller, I. Meineke, K.D. Wernecke, I. Roots, and J. Brockmoller Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics J Clin Psychopharmacol 23 2003 459 466 (Pubitemid 37128673)
161. J. Kirchheiner, J. Sasse, I. Meineke, I. Roots, and J. Brockmoller Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity Pharmacogenetics 13 2003 721 728 (Pubitemid 38429250)
162. J. Kirchheiner, H.B. Henckel, I. Meineke, I. Roots, and J. Brockmoller Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers J Clin Psychopharmacol 24 2004 647 652 (Pubitemid 39518662)
163. J. Kirchheiner, K. Nickchen, J. Sasse, M. Bauer, I. Roots, and J. Brockmoller A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment Pharmacogenomics J 7 2007 48 55 (Pubitemid 46322079)
164. T. Kishi, Y. Fukuo, R. Yoshimura, T. Okochi, T. Kitajima, and H. Naitoh et al. Pharmacogenetic study of serotonin 6 receptor gene with antidepressant response in major depressive disorder in the Japanese population Hum Psychopharmacol 25 2010 481 486
165. E. Klenova, A.C. Scott, J. Roberts, S. Shamsuddin, E.A. Lovejoy, and S. Bergmann et al. YB-1 and CTCF differentially regulate the 5-HTT polymorphic intron 2 enhancer which predisposes to a variety of neurological disorders J Neurosci 24 2004 5966 5973 (Pubitemid 38864781)
166. D.A. Knobelman, R. Hen, and I. Lucki Genetic regulation of extracellular serotonin by 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) autoreceptors in different brain regions of the mouse J Pharmacol Exp Ther 298 2001 1083 1091 (Pubitemid 32761924)
167. N.A. Kocabas, C. Faghel, M. Barreto, S. Kasper, S. Linotte, and J. Mendlewicz et al. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study Int Clin Psychopharmacol 25 2010 218 227
168. S. Koch, K.W. Perry, D.L. Nelson, R.G. Conway, P.G. Threlkeld, and F.P. Bymaster R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study Neuropsychopharmacology 27 2002 949 959 (Pubitemid 35447632)
169. S. Komagata, M. Nakajima, S. Takagi, T. Mohri, T. Taniya, and T. Yokoi Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b Mol Pharmacol 76 2009 702 709
170. E. Koponen, T. Rantamaki, V. Voikar, T. Saarelainen, E. MacDonald, and E. Castren Enhanced BDNF signaling is associated with an antidepressant-like behavioral response and changes in brain monoamines Cell Mol Neurobiol 25 2005 973 980 (Pubitemid 43154821)
171. O. Kovalchuk, J. Filkowski, J. Meservy, Y. Ilnytskyy, V.P. Tryndyak, and V.F. Chekhun et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin Mol Cancer Ther 7 2008 2152 2159
172. J.B. Kraft, S.L. Slager, P.J. McGrath, and S.P. Hamilton Sequence analysis of the serotonin transporter and associations with antidepressant response Biol Psychiatry 58 2005 374 381 (Pubitemid 41219705)
173. S. Kronenberg, A. Apter, D. Brent, S. Schirman, N. Melhem, and N. Pick et al. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders J Child Adolesc Psychopharmacol 17 2007 741 750 (Pubitemid 351158594)
174. H.M. Lachman, D.F. Papolos, T. Saito, Y.M. Yu, C.L. Szumlanski, and R.M. Weinshilboum Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders Pharmacogenetics 6 1996 243 250 (Pubitemid 26226317)
175. B. Laika, S. Leucht, and W. Steimer ABCB1 (P-glycoprotein/MDR1) gene G2677T/A sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline Clin Chem 52 2006 893 895 (Pubitemid 43673271)
176. G. Laje, N. Lally, D. Mathews, N. Brutsche, A. Chemerinski, and N. Akula et al. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients Biol Psychiatry 72 2012 e27 e28
177. Y.W. Lam, A. Gaedigk, L. Ereshefsky, C.L. Alfaro, and J. Simpson CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6 Pharmacotherapy 22 2002 1001 1006 (Pubitemid 34831295)
178. J.M. Launay, S. Mouillet-Richard, A. Baudry, M. Pietri, and O. Kellermann Raphe-mediated signals control the hippocampal response to SRI antidepressants via miR-16 Transl Psychiatry 1 2011 e56
179. S.H. Lee, K.J. Lee, H.J. Lee, B.J. Ham, S.H. Ryu, and M.S. Lee Association between the 5-HT6 receptor C267T polymorphism and response to antidepressant treatment in major depressive disorder Psychiatry Clin Neurosci 59 2005 140 145
180. I. Lee, S.S. Ajay, J.I. Yook, H.S. Kim, S.H. Hong, and N.H. Kim et al. New class of microRNA targets containing simultaneous 5′-UTR and 3′-UTR interaction sites Genome Res 19 2009 1175 1183
181. S.H. Lee, M.S. Lee, J.H. Lee, S.W. Kim, R.H. Kang, and M.J. Choi et al. MRP1 polymorphisms associated with citalopram response in patients with major depression J Clin Psychopharmacol 30 2010 116 125
182. M. Lekman, G. Laje, D. Charney, A.J. Rush, A.F. Wilson, and A.J. Sorant et al. The FKBP5-gene in depression and treatment response - an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) cohort Biol Psychiatry 63 2008 1103 1110
183. S. Lemonde, G. Turecki, D. Bakish, L. Du, P.D. Hrdina, and C.D. Bown et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide J Neurosci 23 2003 8788 8799 (Pubitemid 37176660)
184. S. Lemonde, L. Du, D. Bakish, P. Hrdina, and P.R. Albert Association of the C(- 1019)G 5-HT1A functional promoter polymorphism with antidepressant response Int J Neuropsychopharmacol 7 2004 501 506 (Pubitemid 39648081)
185. K.P. Lesch, D. Bengel, A. Heils, S.Z. Sabol, B.D. Greenberg, and S. Petri et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region Science 274 1996 1527 1531 (Pubitemid 26403928)
186. G.M. Levin, T.M. Bowles, M.J. Ehret, T. Langaee, J.Y. Tan, and J.A. Johnson et al. Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness Mol Diagn Ther 11 2007 155 160 (Pubitemid 46983407)
187. Y. Li, B.W. Luikart, S. Birnbaum, J. Chen, C.H. Kwon, and S.G. Kernie et al. TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment Neuron 59 2008 399 412
188. J. Licinio, C. Dong, and M.L. Wong Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response Arch Gen Psychiatry 66 2009 488 497
189. J.E. Lim, J. Pinsonneault, W. Sadee, and D. Saffen Tryptophan hydroxylase 2 (TPH2) haplotypes predict levels of TPH2 mRNA expression in human pons Mol Psychiatry 12 2007 491 501 (Pubitemid 46652452)
190. K.M. Lin, Y.F. Chiu, I.J. Tsai, C.H. Chen, W.W. Shen, and S.C. Liu et al. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment Pharmacogenet Genomics 21 2011 163 170
191. A.B. Lind, M. Reis, F. Bengtsson, M. Jonzier-Perey, K. Powell Golay, and J. Ahlner et al. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour Clin Pharmacokinet 48 2009 63 70
192. J.S. Lindholm, H. Autio, L. Vesa, H. Antila, L. Lindemann, and M.C. Hoener et al. The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf(+)/(-) heterozygous null mice Neuropharmacology 62 2012 391 397
193. Y.J. Liou, T.J. Chen, S.J. Tsai, Y.W. Yu, C.Y. Cheng, and C.J. Hong Support for the involvement of the KCNK2 gene in major depressive disorder and response to antidepressant treatment Pharmacogenet Genomics 19 2009 735 741
194. A. Lira, M. Zhou, N. Castanon, M.S. Ansorge, J.A. Gordon, and J.H. Francis et al. Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice Biol Psychiatry 54 2003 960 971 (Pubitemid 37415032)
195. Z.Q. Liu, Z.N. Cheng, S.L. Huang, X.P. Chen, D.S. Ou-Yang, and C.H. Jiang et al. Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects Br J Clin Pharmacol 52 2001 96 99
196. R.J. Liu, F.S. Lee, X.Y. Li, F. Bambico, R.S. Duman, and G.K. Aghajanian Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex Biol Psychiatry 71 2012 996 1005
197. A. Llerena, P. Dorado, R. Berecz, A.P. Gonzalez, and L.E.M. Penas Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions Eur J Clin Pharmacol 59 2004 869 873 (Pubitemid 38337438)
198. M.K. Lobo, E.J. Nestler, and H.E. Covington III Potential utility of optogenetics in the study of depression Biol Psychiatry 71 2012 1068 1074
199. E.A. Lovejoy, A.C. Scott, C.E. Fiskerstrand, V.J. Bubb, and J.P. Quinn The serotonin transporter intronic VNTR enhancer correlated with a predisposition to affective disorders has distinct regulatory elements within the domain based on the primary DNA sequence of the repeat unit Eur J Neurosci 17 2003 417 420 (Pubitemid 36459521)
200. B. Lu, P.T. Pang, and N.H. Woo The yin and yang of neurotrophin action Nat Rev Neurosci 6 2005 603 614 (Pubitemid 41059335)
201. S. Lucae, M. Ising, S. Horstmann, B.T. Baune, V. Arolt, and B. Muller-Myhsok et al. HTR2A gene variation is involved in antidepressant treatment response Eur Neuropsychopharmacol 20 2010 65 68
202. G. Lucas, V.V. Rymar, J. Du, O. Mnie-Filali, C. Bisgaard, and S. Manta et al. Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action Neuron 55 2007 712 725 (Pubitemid 47334877)
203. I. Lucki, and O.F. O'Leary Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs J Clin Psychiatry 65 Suppl. 4 2004 11 24
204. A. MacKenzie, and J. Quinn A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo Proc Natl Acad Sci U S A 96 1999 15251 15255 (Pubitemid 30019798)
205. M. Maes, C. Song, and R. Yirmiya Targeting IL-1 in depression Expert Opin Ther Targets 16 2012 1097 1112
206. K.M. Mahar Doan, J.E. Humphreys, L.O. Webster, S.A. Wring, L.J. Shampine, and C.J. Serabjit-Singh et al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs J Pharmacol Exp Ther 303 2002 1029 1037 (Pubitemid 35424386)
207. I. Malagie, D.J. David, P. Jolliet, R. Hen, M. Bourin, and A.M. Gardier Improved efficacy of fluoxetine in increasing hippocampal 5-hydroxytryptamine outflow in 5-HT(1B) receptor knock-out mice Eur J Pharmacol 443 2002 99 104 (Pubitemid 34603603)
208. A. Malaguti, D. Rossini, A. Lucca, L. Magri, C. Lorenzi, and A. Pirovano et al. Role of COMT, 5-HT(1A), and SERT genetic polymorphisms on antidepressant response to transcranial magnetic stimulation Depress Anxiety 28 2011 568 573
209. P. Mandela, and G.A. Ordway The norepinephrine transporter and its regulation J Neurochem 97 2006 310 333
210. E. Maron, A. Tammiste, K. Kallassalu, T. Eller, V. Vasar, and D.J. Nutt et al. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression Eur Neuropsychopharmacol 19 2009 451 456
211. C. Marzolini, E. Paus, T. Buclin, and R.B. Kim Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance Clin Pharmacol Ther 75 2004 13 33 (Pubitemid 38130115)
212. B.L. Mason, C.M. Pariante, and S.A. Thomas Changes in the brain accumulation of glucocorticoids in abcb1a-deficient CF-1 mice J Neuroendocrinol 24 2012 1440 1446
213. A.J. Mayorga, A. Dalvi, M.E. Page, S. Zimov-Levinson, R. Hen, and I. Lucki Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice J Pharmacol Exp Ther 298 2001 1101 1107 (Pubitemid 32761926)
214. F.J. McMahon, S. Buervenich, D. Charney, R. Lipsky, A.J. Rush, and A.F. Wilson et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment Am J Hum Genet 78 2006 804 814
215. J.M. Meerum Terwogt, M.M. Malingre, J.H. Beijnen, W.W. ten Bokkel Huinink, H. Rosing, and F.J. Koopman et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel Clin Cancer Res 5 1999 3379 3384
216. A. Menke, T. Klengel, and E.B. Binder Epigenetics, depression and antidepressant treatment Curr Pharm Des 18 2012 5879 5889
217. A. Mihaljevic Peles, N. Bozina, M. Sagud, M. Rojnic Kuzman, and M. Lovric MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression Prog Neuropsychopharmacol Biol Psychiatry 32 2008 1439 1444
218. W. Min, T. Li, X. Ma, Z. Li, T. Yu, and D. Gao et al. Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response Psychopharmacology (Berl) 205 2009 409 417
219. C. Minov, T.C. Baghai, C. Schule, P. Zwanzger, M.J. Schwarz, and P. Zill et al. Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression Neurosci Lett 303 2001 119 122 (Pubitemid 32320019)
220. P.J. Mishra, R. Humeniuk, G.S. Longo-Sorbello, D. Banerjee, and J.R. Bertino A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance Proc Natl Acad Sci U S A 104 2007 13513 13518 (Pubitemid 47293976)
221. L.M. Monteggia, M. Barrot, C.M. Powell, O. Berton, V. Galanis, and T. Gemelli et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function Proc Natl Acad Sci U S A 101 2004 10827 10832 (Pubitemid 38955827)
222. L.M. Monteggia, B. Luikart, M. Barrot, D. Theobold, I. Malkovska, and S. Nef et al. Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors Biol Psychiatry 61 2007 187 197 (Pubitemid 46072778)
223. S. Morinobu, T. Tanaka, S. Kawakatsu, S. Totsuka, E. Koyama, and K. Chiba et al. Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy Psychiatry Clin Neurosci 51 1997 253 257 (Pubitemid 27362560)
224. S. Morita, K. Shimoda, T. Someya, Y. Yoshimura, K. Kamijima, and N. Kato Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline J Clin Psychopharmacol 20 2000 141 149 (Pubitemid 30202355)
225. R. Mossner, R. Simantov, A. Marx, K.P. Lesch, and I. Seif Aberrant accumulation of serotonin in dopaminergic neurons Neurosci Lett 401 2006 49 54
226. D.A. Mrazek, A.J. Rush, J.M. Biernacka, D.J. O'Kane, J.M. Cunningham, and E.D. Wieben et al. SLC6A4 variation and citalopram response Am J Med Genet B Neuropsychiatr Genet 150B 2009 341 351
227. H. Mulder, A. Herder, F.W. Wilmink, W.J. Tamminga, S.V. Belitser, and A.C. Egberts The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice Pharmacoepidemiol Drug Saf 15 2006 107 114
228. E. Murphy, and F.J. McMahon Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations Discov Med 16 2013 113 122
229. G.M. Murphy Jr., C. Kremer, H.E. Rodrigues, and A.F. Schatzberg Pharmacogenetics of antidepressant medication intolerance Am J Psychiatry 160 2003 1830 1835 (Pubitemid 41103318)
230. D.L. Murphy, A. Lerner, G. Rudnick, and K.P. Lesch Serotonin transporter: gene, genetic disorders, and pharmacogenetics Mol Interv 4 2004 109 123 (Pubitemid 38584973)
231. N.V. Murthy, S. Selvaraj, P.J. Cowen, Z. Bhagwagar, W.J. Riedel, and P. Peers et al. Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain Neuroimage 52 2010 50 54
232. L. Musazzi, G. Treccani, A. Mallei, and M. Popoli The action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptors Biological psychiatry 73 2013 1180 1188
233. K. Nakamura, Y. Sugawara, K. Sawabe, A. Ohashi, H. Tsurui, and Y. Xiu et al. Late developmental stage-specific role of tryptophan hydroxylase 1 in brain serotonin levels J Neurosci 26 2006 530 534 (Pubitemid 43237117)
234. S. Narasimhan, and F.W. Lohoff Pharmacogenetics of antidepressant drugs: current clinical practice and future directions Pharmacogenomics 13 2012 441 464
235. J.C. Nelson, C.M. Mazure, and P.I. Jatlow Desipramine treatment of major depression in patients over 75 years of age J Clin Psychopharmacol 15 1995 99 105
236. E.J. Nestler, and W.A. Carlezon Jr. The mesolimbic dopamine reward circuit in depression Biol Psychiatry 59 2006 1151 1159 (Pubitemid 44192421)
237. A.I. Nichols, K. Lobello, C.J. Guico-Pabia, J. Paul, and S.H. Preskorn Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status J Clin Psychopharmacol 29 2009 383 386
238. G. Nikisch, C.B. Eap, and P. Baumann Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study Pharmacol Res 58 2008 344 347
239. C. Normann, M. Horn, B. Hummel, H. Grunze, and J. Walden Paroxetine in major depression: correlating plasma concentrations and clinical response Pharmacopsychiatry 37 2004 123 126 (Pubitemid 38680333)
240. C.D. Novina, and P.A. Sharp The RNAi revolution Nature 430 2004 161 164 (Pubitemid 38902417)
241. F.E. O'Brien, G. Clarke, P. Fitzgerald, T.G. Dinan, B.T. Griffin, and J.F. Cryan Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats Br J Pharmacol 166 2012 1333 1343
242. F.E. O'Brien, T.G. Dinan, B.T. Griffin, and J.F. Cryan Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings Br J Pharmacol 165 2012 289 312
243. F.E. O'Brien, R.M. O'Connor, G. Clarke, T.G. Dinan, B.T. Griffin, and J.F. Cryan P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents Neuropsychopharmacology 38 2013 2209 2219
244. F.E. O'Brien, G. Clarke, T.G. Dinan, J.F. Cryan, and B.T. Griffin Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability Int J Neuropsychopharmacol 2013 1 14
245. R.M. O'Connor, B.C. Finger, P.J. Flor, and J.F. Cryan Metabotropic glutamate receptor 7: at the interface of cognition and emotion Eur J Pharmacol 639 2010 123 131
246. R.M. O'Connor, T.G. Dinan, and J.F. Cryan Little things on which happiness depends: microRNAs as novel therapeutic targets for the treatment of anxiety and depression Mol Psychiatry 17 2012 359 376
247. R.M. O'Connor, S. Grenham, T.G. Dinan, and J.F. Cryan microRNAs as novel antidepressant targets: converging effects of ketamine and electroconvulsive shock therapy in the rat hippocampus The international journal of neuropsychopharmacology 16 2013 1885 1892
248. O.F. O'Leary, and E. Castren Neurotrophic factors and antidepressant action: Recent advances J.F. Cryan, B.E. Leonard, Depression: from psychopathology to pharmacotherapy 2010 Karger Basel 199 223
249. O.F. O'Leary, and J.F. Cryan The tail suspension test: a model for characterizing antidepressant activity in mice T. Gould, Mood & anxiety related phenotypes in mice 2009 Springer USA 119 137
250. O.F. O'Leary, and J.F. Cryan The behavioural genetics of serotonin: relevance to anxiety and depression C.P. Muller, B.L. Jacobs, Handbook of the behavioral neurobiology of serotonin 2010 Academic Press USA 749 791
251. O.F. O'Leary, and J.F. Cryan Towards translational rodent models of depression Cell Tissue Res 354 1 2013 141 153
252. O.F. O'Leary, A.J. Bechtholt, J.J. Crowley, T.E. Hill, M.E. Page, and I. Lucki Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test Psychopharmacology (Berl) 192 2007 357 371 (Pubitemid 46701581)
253. O.F. O'Leary, X. Wu, and E. Castren Chronic fluoxetine treatment increases expression of synaptic proteins in the hippocampus of the ovariectomized rat: role of BDNF signalling Psychoneuroendocrinology 34 2009 367 381
254. O.F. O'Leary, S. Zandy, T.G. Dinan, and J.F. Cryan Lithium augmentation of the effects of desipramine in a mouse model of treatment-resistant depression: a role for hippocampal cell proliferation Neuroscience 228 2013 36 46
255. J.D. Olivier, M.G. Van Der Hart, R.P. Van Swelm, P.J. Dederen, J.R. Homberg, and T. Cremers et al. A study in male and female 5-HT transporter knockout rats: an animal model for anxiety and depression disorders Neuroscience 152 2008 573 584
256. V. Ozdemir, R.F. Tyndale, K. Reed, N. Herrmann, E.M. Sellers, and W. Kalow et al. Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers J Clin Psychopharmacol 19 1999 472 475 (Pubitemid 29451514)
257. S. Paddock, G. Laje, D. Charney, A.J. Rush, A.F. Wilson, and A.J. Sorant et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort Am J Psychiatry 164 2007 1181 1188 (Pubitemid 47292406)
258. C.U. Pae, A. Chiesa, S. Porcelli, C. Han, A.A. Patkar, and S.J. Lee et al. Influence of BDNF variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia Neuropsychobiology 65 2012 1 11
259. M.E. Page, M.J. Detke, A. Dalvi, L.G. Kirby, and I. Lucki Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test Psychopharmacology (Berl) 147 1999 162 167 (Pubitemid 30010563)
260. P. Palanza Animal models of anxiety and depression: how are females different? Neurosci Biobehav Rev 25 2001 219 233 (Pubitemid 32506875)
261. Y.Z. Pan, W. Gao, and A.M. Yu MicroRNAs regulate CYP3A4 expression via direct and indirect targeting Drug Metab Dispos 37 2009 2112 2117
262. J. Pascual-Brazo, E. Castro, A. Diaz, E.M. Valdizan, F. Pilar-Cuellar, and R. Vidal et al. Modulation of neuroplasticity pathways and antidepressant-like behavioural responses following the short-term (3 and 7 days) administration of the 5-HT(4) receptor agonist RS67333 Int J Neuropsychopharmacol 15 2012 631 643
263. E.K.J. Pauwels, P. Erba, G. Mariani, and C.M.F. Gomes Multidrug resistance in cancer: its mechanism and its modulation Drug News Perspect 20 2007 371 377 (Pubitemid 350219069)
264. M.L. Pergadia, A.L. Glowinski, N.R. Wray, A. Agrawal, S.F. Saccone, and A. Loukola et al. A 3p26-3p25 genetic linkage finding for DSM-IV major depression in heavy smoking families Am J Psychiatry 168 2011 848 852
265. R.H. Perlis, P. Moorjani, J. Fagerness, S. Purcell, M.H. Trivedi, and M. Fava et al. Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study Neuropsychopharmacology 33 2008 2810 2819
266. R.H. Perlis, B. Fijal, D.H. Adams, V.K. Sutton, M.H. Trivedi, and J.P. Houston Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder Biol Psychiatry 65 2009 785 791
267. R.H. Perlis, B. Fijal, S. Dharia, A.N. Heinloth, and J.P. Houston Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients Biol Psychiatry 67 2010 1110 1113
268. G. Perna, E. Favaron, D. Di Bella, R. Bussi, and L. Bellodi Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene Neuropsychopharmacology 30 2005 2230 2235 (Pubitemid 41643974)
269. M.T. Perona, S. Waters, F.S. Hall, I. Sora, K.P. Lesch, and D.L. Murphy et al. Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions Behav Pharmacol 19 2008 566 574
270. P.J. Perry, B.M. Pfohl, and S.G. Holstad The relationship between antidepressant response and tricyclic antidepressant plasma concentrations. A retrospective analysis of the literature using logistic regression analysis Clin Pharmacokinet 13 1987 381 392 (Pubitemid 18018786)
271. E.J. Peters, S.L. Slager, P.J. McGrath, J.A. Knowles, and S.P. Hamilton Investigation of serotonin-related genes in antidepressant response Mol Psychiatry 9 2004 879 889 (Pubitemid 39273536)
272. E.J. Peters, S.L. Slager, J.B. Kraft, G.D. Jenkins, M.S. Reinalda, and P.J. McGrath et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample PLoS One 3 2008
273. E.J. Peters, S.L. Slager, G.D. Jenkins, M.S. Reinalda, H.A. Garriock, and S.I. Shyn et al. Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response Pharmacogenet Genomics 19 2009 1 10
274. M.E. Peters, V. Vaidya, L.T. Drye, P.B. Rosenberg, B.K. Martin, and A.P. Porsteinsson et al. Sertraline for the treatment of depression in Alzheimer disease: genetic influences J Geriatr Psychiatry Neurol 24 2011 222 228
275. B.G. Pollock, R.E. Ferrell, B.H. Mulsant, S. Mazumdar, M. Miller, and R.A. Sweet et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression Neuropsychopharmacology 23 2000 587 590
276. S. Porcelli, A. Drago, C. Fabbri, S. Gibiino, R. Calati, and A. Serretti
277. S. Porcelli, C. Fabbri, E. Spina, A. Serretti, and D. De Ronchi Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism Expert Opin Drug Metab Toxicol 7 2011 1101 1115
278. S. Porcelli, C. Fabbri, and A. Serretti Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy Eur Neuropsychopharmacol 22 2012 239 258
279. H. Potschka Role of CNS efflux drug transporters in antiepileptic drug delivery: overcoming CNS efflux drug transport Adv Drug Deliv Rev 64 2012 943 952
280. S.H. Preskorn, C.P. Kane, K. Lobello, A.I. Nichols, R. Fayyad, and G. Buckley et al. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine J Clin Psychiatry 74 6 2013 614 621
281. P. Pruunsild, A. Kazantseva, T. Aid, K. Palm, and T. Timmusk Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters Genomics 90 2007 397 406 (Pubitemid 47179877)
282. G. Quesseveur, H.T. Nguyen, A.M. Gardier, and B.P. Guiard 5-HT2 ligands in the treatment of anxiety and depression Expert Opin Investig Drugs 21 2012 1701 1725
283. G. Racagni, M.A. Riva, R. Molteni, L. Musazzi, F. Calabrese, and M. Popoli et al. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors World J Biol Psychiatry 12 2011 574 587
284. T. Rau, G. Wohlleben, H. Wuttke, N. Thuerauf, J. Lunkenheimer, and M. Lanczik et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study Clin Pharmacol Ther 75 2004 386 393 (Pubitemid 38534559)
285. J.L. Rausch, M.E. Johnson, Y.J. Fei, J.Q. Li, N. Shendarkar, and H.M. Hobby et al. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome Biol Psychiatry 51 2002 723 732 (Pubitemid 34450808)
286. R.L. Roberts, P.R. Joyce, R.T. Mulder, E.J. Begg, and M.A. Kennedy A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression Pharmacogenomics J 2 2002 191 196 (Pubitemid 34982226)
287. S.P. Roose, A.H. Glassman, E. Attia, and S. Woodring Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia Am J Psychiatry 151 1994 1735 1739 (Pubitemid 24370892)
288. B.M. Ruf, and Z. Bhagwagar The 5-HT1B receptor: a novel target for the pathophysiology of depression Curr Drug Targets 10 2009 1118 1138
289. T. Saarelainen, P. Hendolin, G. Lucas, E. Koponen, M. Sairanen, and E. MacDonald et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects J Neurosci 23 2003 349 357 (Pubitemid 36050437)
290. S.Z. Sabol, S. Hu, and D. Hamer A functional polymorphism in the monoamine oxidase A gene promoter Hum Genet 103 1998 273 279 (Pubitemid 28470076)
291. M. Sairanen, G. Lucas, P. Ernfors, M. Castren, and E. Castren Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus J Neurosci 25 2005 1089 1094 (Pubitemid 40268949)
292. K. Sakata, J.R. Mastin, S.M. Duke, M.G. Vail, A.E. Overacre, and B.E. Dong et al. Effects of antidepressant treatment on mice lacking brain-derived neurotrophic factor expression through promoter IV Eur J Neurosci 37 11 2013 1863 1874
293. F.R. Sallee, C.L. DeVane, and R.E. Ferrell Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency J Child Adolesc Psychopharmacol 10 2000 27 34 (Pubitemid 30155425)
294. B.A. Samuels, E.D. Leonardo, R. Gadient, A. Williams, J. Zhou, and D.J. David et al. Modeling treatment-resistant depression Neuropharmacology 61 2011 408 413
295. L. Santarelli, M. Saxe, C. Gross, A. Surget, F. Battaglia, and S. Dulawa et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants Science 301 2003 805 809 (Pubitemid 36962615)
296. J.E. Sarginson, L.C. Lazzeroni, H.S. Ryan, B.D. Ershoff, A.F. Schatzberg, and G.M. Murphy ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression Pharmacogenet Genomics 20 2010 467 475
297. J.E. Sarginson, L.C. Lazzeroni, H.S. Ryan, A.F. Schatzberg, and G.M. Murphy Jr. FKBP5 polymorphisms and antidepressant response in geriatric depression Am J Med Genet B Neuropsychiatr Genet 153B 2010 554 560
298. K. Sato, K. Yoshida, H. Takahashi, K. Ito, M. Kamata, and H. Higuchi et al. Association between - 1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder Neuropsychobiology 46 2002 136 140
299. A. Sato, Y. Okura, S. Minagawa, Y. Ohno, S. Fujita, and D. Kondo et al. Life-threatening serotonin syndrome in a patient with chronic heart failure and CYP2D6*1/*5 Mayo Clin Proc 79 2004 1444 1448 (Pubitemid 39453311)
300. E. Saus, V. Soria, G. Escaramis, F. Vivarelli, J.M. Crespo, and B. Kagerbauer et al. Genetic variants and abnormal processing of pre-miR-182, a circadian clock modulator, in major depression patients with late insomnia Hum Mol Genet 19 2010 4017 4025
301. K. Sawamura, Y. Suzuki, and T. Someya Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine Eur J Clin Pharmacol 60 2004 553 557 (Pubitemid 39517907)
302. P.W. Schenk, M.A. van Fessem, S. Verploegh-Van Rij, R.A. Mathot, T. van Gelder, and A.G. Vulto et al. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients Mol Psychiatry 13 2008 597 605 (Pubitemid 351704935)
303. A.H. Schinkel P-Glycoprotein, a gatekeeper in the blood-brain barrier Adv Drug Deliv Rev 36 1999 179 194 (Pubitemid 29121971)
304. A.H. Schinkel, J.J.M. Smit, O. Vantellingen, J.H. Beijnen, E. Wagenaar, and L. Vandeemter et al. Disruption of the mouse Mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain-barrier and to increased sensitivity to drugs Cell 77 1994 491 502 (Pubitemid 24153990)
305. A.H. Schinkel, E. Wagenaar, C.A. Mol, and L. van Deemter P-Glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs J Clin Invest 97 1996 2517 2524 (Pubitemid 26187339)
306. A.H. Schinkel, U. Mayer, E. Wagenaar, C.A.A.M. Mol, L. vanDeemter, and J.J.M. Smit Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins Proc Natl Acad Sci U S A 94 1997 4028 4033 (Pubitemid 27180493)
307. T.E. Schlaepfer, H. Agren, P. Monteleone, C. Gasto, W. Pitchot, and F. Rouillon et al. The hidden third: improving outcome in treatment-resistant depression J Psychopharmacol 26 2012 587 602
308. Y. Schoenfelder, C. Hiemke, and U. Schmitt Behavioural consequences of p-glycoprotein deficiency in mice, with special focus on stress-related mechanisms J Neuroendocrinol 24 2012 809 817
309. A. Schosser, A. Serretti, D. Souery, J. Mendlewicz, J. Zohar, and S. Montgomery et al. European Group for the Study of Resistant Depression (GSRD) - where have we gone so far: review of clinical and genetic findings Eur Neuropsychopharmacol 22 2012 453 468
310. S. Schuldiner, A. Shirvan, and M. Linial Vesicular neurotransmitter transporters: from bacteria to humans Physiol Rev 75 1995 369 392
311. M.G. Scordo, E. Spina, M.L. Dahl, G. Gatti, and E. Perucca Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine Basic Clin Pharmacol Toxicol 97 2005 296 301 (Pubitemid 41608122)
312. A.L. Scott, M. Bortolato, K. Chen, and J.C. Shih Novel monoamine oxidase A knock out mice with human-like spontaneous mutation Neuroreport 19 2008 739 743 (Pubitemid 351555982)
313. A. Serretti, R. Lilli, C. Lorenzi, M. Gasperini, and E. Smeraldi Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders J Psychiatr Res 33 1999 371 377 (Pubitemid 29392685)
314. A. Serretti, R. Zanardi, C. Cusin, D. Rossini, C. Lorenzi, and E. Smeraldi Tryptophan hydroxylase gene associated with paroxetine antidepressant activity Eur Neuropsychopharmacol 11 2001 375 380 (Pubitemid 32946888)
315. A. Serretti, R. Zanardi, D. Rossini, C. Cusin, R. Lilli, and E. Smeraldi Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity Mol Psychiatry 6 2001 586 592 (Pubitemid 32772568)
316. A. Serretti, P. Artioli, C. Lorenzi, A. Pirovano, V. Tubazio, and R. Zanardi The C(- 1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings Int J Neuropsychopharmacol 7 2004 453 460 (Pubitemid 39648075)
317. A. Serretti, C. Cusin, D. Rossini, P. Artioli, D. Dotoli, and R. Zanardi Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders Am J Med Genet B Neuropsychiatr Genet 129B 2004 36 40 (Pubitemid 38989065)
318. A. Serretti, R. Zanardi, L. Franchini, P. Artioli, D. Dotoli, and A. Pirovano et al. Pharmacogenetics of selective serotonin reuptake inhibitor response: a 6-month follow-up Pharmacogenetics 14 2004 607 613 (Pubitemid 39281815)
319. A. Serretti, M. Kato, D. De Ronchi, and T. Kinoshita Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients Mol Psychiatry 12 2007 247 257 (Pubitemid 46328503)
320. A. Serretti, M. Kato, and J.L. Kennedy Pharmacogenetic studies in depression: a proposal for methodologic guidelines Pharmacogenomics J 8 2008 90 100 (Pubitemid 351411545)
321. A. Serretti, R. Calati, I. Massat, S. Linotte, S. Kasper, and Y. Lecrubier et al. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients Int Clin Psychopharmacol 24 2009 250 256
322. A. Serretti, A. Chiesa, S. Porcelli, C. Han, A.A. Patkar, and S.J. Lee et al. Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia Psychiatry Res 189 2011 26 32
323. A. Serretti, A. Chiesa, C. Crisafulli, I. Massat, S. Linotte, and R. Calati et al. Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression Neuropsychobiology 65 2012 70 75
324. M.E. Shams, B. Arneth, C. Hiemke, A. Dragicevic, M.J. Muller, and R. Kaiser et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine J Clin Pharm Ther 31 2006 493 502 (Pubitemid 44337299)
325. K. Shimoda, T. Someya, A. Yokono, S. Morita, G. Hirokane, and S. Takahashi et al. The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients J Clin Psychopharmacol 22 2002 371 378 (Pubitemid 34810326)
326. K. Shioe, T. Ichimiya, T. Suhara, A. Takano, Y. Sudo, and F. Yasuno et al. No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET Synapse 48 2003 184 188 (Pubitemid 36520652)
327. S.I. Shyn, J. Shi, J.B. Kraft, J.B. Potash, J.A. Knowles, and M.M. Weissman et al. Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies Mol Psychiatry 16 2011 202 215
328. W.B. Siesser, X. Zhang, J.P. Jacobsen, T.D. Sotnikova, R.R. Gainetdinov, and M.G. Caron Tryptophan hydroxylase 2 genotype determines brain serotonin synthesis but not tissue content in C57Bl/6 and BALB/c congenic mice Neurosci Lett 481 2010 6 11
329. W.B. Siesser, B.D. Sachs, A.J. Ramsey, T.D. Sotnikova, J.M. Beaulieu, and X. Zhang et al. Chronic SSRI treatment exacerbates serotonin deficiency in humanized Tph2 mutant mice ACS Chem Neurosci 4 2013 84 88
330. A.B. Singh, C.A. Bousman, C.H. Ng, K. Byron, and M. Berk ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression Transl Psychiatry 2 2012 e198
331. A.B. Singh, C.A. Bousman, C.H. Ng, K. Byron, and M. Berk Psychomotor depressive symptoms may differentially respond to venlafaxine Int Clin Psychopharmacol 28 2013 121 126
332. E. Smeraldi, R. Zanardi, F. Benedetti, D. Di Bella, J. Perez, and M. Catalano Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine Mol Psychiatry 3 1998 508 511 (Pubitemid 28515526)
333. D.J. Smith, S. Kyle, L. Forty, C. Cooper, J. Walters, and E. Russell et al. Differences in depressive symptom profile between males and females J Affect Disord 108 2008 279 284 (Pubitemid 351615439)
334. L.A. Smit-Rigter, C.W. Noorlander, L. von Oerthel, P. Chameau, M.P. Smidt, and J.A. van Hooft Prenatal fluoxetine exposure induces life-long serotonin 5-HT(3) receptor-dependent cortical abnormalities and anxiety-like behaviour Neuropharmacology 62 2012 865 870
335. E. Spina, C. Gitto, A. Avenoso, G.M. Campo, A.P. Caputi, and E. Perucca Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study Eur J Clin Pharmacol 51 1997 395 398 (Pubitemid 27055908)
336. A. Spudich, E. Kilic, H.Y. Xing, U. Kilic, K.M. Rentsch, and H. Wunderli-Allenspach et al. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia Nat Neurosci 9 2006 487 488
337. C.A. Stedman, E.J. Begg, M.A. Kennedy, R. Roberts, and T.J. Wilkinson Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia Hum Psychopharmacol 17 2002 187 190 (Pubitemid 34678880)
338. W. Steimer, K. Zopf, S. von Amelunxen, H. Pfeiffer, J. Bachofer, and J. Popp et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers Clin Chem 50 2004 1623 1633 (Pubitemid 39121231)
339. W. Steimer, K. Zopf, S. von Amelunxen, H. Pfeiffer, J. Bachofer, and J. Popp et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy Clin Chem 51 2005 376 385 (Pubitemid 40175808)
340. N. Su, L. Zhang, F. Fei, H. Hu, K. Wang, and H. Hui et al. The brain-derived neurotrophic factor is associated with alcohol dependence-related depression and antidepressant response Brain Res 1415 2011 119 126
341. T. Sugai, Y. Suzuki, K. Sawamura, N. Fukui, Y. Inoue, and T. Someya The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine Pharmacogenomics J 6 2006 351 356 (Pubitemid 44480155)
342. Y. Suzuki, K. Sawamura, and T. Someya The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients Pharmacogenomics J 4 2004 283 286 (Pubitemid 39136772)
343. P. Svenningsson, K. Chergui, I. Rachleff, M. Flajolet, X. Zhang, and M. El Yacoubi et al. Alterations in 5-HT1B receptor function by p11 in depression-like states Science 311 2006 77 80 (Pubitemid 43063061)
344. P. Svenningsson, E.T. Tzavara, H. Qi, R. Carruthers, J.M. Witkin, and G.G. Nomikos et al. Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation J Neurosci 27 2007 4201 4209 (Pubitemid 46597167)
345. C.J. Swanson, M. Bures, M.P. Johnson, A.M. Linden, J.A. Monn, and D.D. Schoepp Metabotropic glutamate receptors as novel targets for anxiety and stress disorders Nat Rev Drug Discov 4 2005 131 144 (Pubitemid 40277494)
346. S. Syvanen, O. Lindhe, M. Palner, B.R. Kornum, O. Rahman, and B. Langstrom et al. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport Drug Metab Dispos 37 2009 635 643
347. A. Szegedi, D. Rujescu, A. Tadic, M.J. Muller, R. Kohnen, and H.H. Stassen et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression Pharmacogenomics J 5 2005 49 53 (Pubitemid 40220617)
348. A. Tadic, M.J. Muller, D. Rujescu, R. Kohnen, H.H. Stassen, and N. Dahmen et al. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression Am J Med Genet B Neuropsychiatr Genet 144B 2007 325 331 (Pubitemid 46642022)
349. M. Tanaka, D. Kobayashi, Y. Murakami, N. Ozaki, T. Suzuki, and N. Iwata et al. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea Int J Neuropsychopharmacol 11 2008 261 267 (Pubitemid 351231828)
350. M.J. Taylor, S. Sen, and Z. Bhagwagar Antidepressant response and the serotonin transporter gene-linked polymorphic region Biol Psychiatry 68 2010 536 543
351. W.D. Taylor, D.R. McQuoid, A. Ashley-Koch, J.R. MacFall, J. Bridgers, and R.R. Krishnan et al. BDNF Val66Met genotype and 6-month remission rates in late-life depression Pharmacogenomics J 11 2011 146 154
352. K. Tenner, F. Qadri, B. Bert, J.P. Voigt, and M. Bader The mTPH2 C1473G single nucleotide polymorphism is not responsible for behavioural differences between mouse strains Neurosci Lett 431 2008 21 25
353. D.R. Thakker, F. Natt, D. Husken, H. van der Putten, R. Maier, and D. Hoyer et al. siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain Mol Psychiatry 10 2005 782 789 [14] (Pubitemid 41129051)
354. F. Thiebaut, T. Tsuruo, H. Hamada, M.M. Gottesman, I. Pastan, and M.C. Willingham Immunohistochemical localization in normal-tissues of different epitopes in the multidrug transport protein P170 - evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein J Histochem Cytochem 37 1989 159 164 (Pubitemid 19039163)
355. H. Thoenen Neurotrophins and neuronal plasticity Science 270 1995 593 598
356. S.A. Thomas, A.M. Matsumoto, and R.D. Palmiter Noradrenaline is essential for mouse fetal development Nature 374 1995 643 646
357. M. Togsverd, T.M. Werge, L.B. Tanko, Y.Z. Bagger, T. Hansen, and G. Qin et al. Association of a dopamine beta-hydroxylase gene variant with depression in elderly women possibly reflecting noradrenergic dysfunction J Affect Disord 106 2008 169 172 (Pubitemid 350309676)
358. T.S. Tracy, R. Venkataramanan, D.D. Glover, and S.N. Caritis Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy Am J Obstet Gynecol 192 2005 633 639 (Pubitemid 40215007)
359. M.H. Trivedi, A.J. Rush, S.R. Wisniewski, A.A. Nierenberg, D. Warden, and L. Ritz et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice Am J Psychiatry 163 2006 28 40 (Pubitemid 43050100)
360. S.J. Tsai, C.J. Hong, Y.W. Yu, T.J. Chen, Y.C. Wang, and W.K. Lin Association study of serotonin 1B receptor (A-161T) genetic polymorphism and suicidal behaviors and response to fluoxetine in major depressive disorder Neuropsychobiology 50 2004 235 238 (Pubitemid 39279417)
361. S.J. Tsai, Y.T. Gau, C.J. Hong, Y.J. Liou, Y.W. Yu, and T.J. Chen Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients J Affect Disord 113 2009 183 187
362. M.H. Tsai, K.M. Lin, M.C. Hsiao, W.W. Shen, M.L. Lu, and H.S. Tang et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response Pharmacogenomics 11 2010 537 546
363. Y. Tsuchiya, M. Nakajima, S. Takagi, T. Taniya, and T. Yokoi MicroRNA regulates the expression of human cytochrome P450 1B1 Cancer Res 66 2006 9090 9098 (Pubitemid 44521128)
364. T. Tsunoka, T. Kishi, M. Ikeda, T. Kitajima, Y. Yamanouchi, and Y. Kinoshita et al. Association analysis of group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population Prog Neuropsychopharmacol Biol Psychiatry 33 2009 875 879
365. K.M. Tye, and K. Deisseroth Optogenetic investigation of neural circuits underlying brain disease in animal models Nat Rev Neurosci 13 2012 251 266
366. D.S. Tzeng, C.C. Chien, F.W. Lung, and C.Y. Yang MAOA gene polymorphisms and response to mirtazapine in major depression Hum Psychopharmacol 24 2009 293 300
367. M.V. Tzvetkov, J. Brockmoller, I. Roots, and J. Kirchheiner Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment Pharmacogenet Genomics 18 2008 495 506 (Pubitemid 351769917)
368. M. Ueda, G. Hirokane, S. Morita, M. Okawa, T. Watanabe, and K. Akiyama et al. The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients Prog Neuropsychopharmacol Biol Psychiatry 30 2006 486 491 (Pubitemid 43841741)
369. R. Uher The implications of gene-environment interactions in depression: will cause inform cure? Mol Psychiatry 13 2008 1070 1078
370. R. Uher, P. Huezo-Diaz, N. Perroud, R. Smith, M. Rietschel, and O. Mors et al. Genetic predictors of response to antidepressants in the GENDEP project Pharmacogenomics J 9 2009 225 233
371. M. Uhr, and M.T. Grauer abcblab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice J Psychiatr Res 37 2003 179 185 (Pubitemid 36313270)
372. M. Uhr, T. Steckler, A. Yassouridis, and F. Holsboer Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to Mdr1a P-glycoprotein gene disruption Neuropsychopharmacology 22 2000 380 387 (Pubitemid 30105766)
373. M. Uhr, M.T. Grauer, and F. Holsboer Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption Biol Psychiatry 54 2003 840 846 (Pubitemid 37205136)
374. M. Uhr, M.T. Grauer, A. Yassouridis, and M. Ebinger Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls J Psychiatr Res 41 2007 179 188 (Pubitemid 44708204)
375. M. Uhr, A. Tontsch, C. Namendorf, S. Ripke, S. Lucae, and M. Ising et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression Neuron 57 2008 203 209
376. A. Van Den Bogaert, S. De Zutter, L. Heyrman, J. Mendlewicz, R. Adolfsson, and C. Van Broeckhoven et al. Response to Zhang et al (2005): loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression Neuron 45 2005 11 16 (Neuron. 2005; 48:704; author reply 5-6)
377. V. Vialou, J. Feng, A.J. Robison, and E.J. Nestler Epigenetic mechanisms of depression and antidepressant action Annu Rev Pharmacol Toxicol 53 2013 59 87
378. E. Vieta, and F. Colom Therapeutic options in treatment-resistant depression Ann Med 43 2011 512 530
379. N.C. Vulink, H.G. Westenberg, F. van Nieuwerburgh, D. Deforce, S.B. Fluitman, and J.S. Meinardi et al. Catechol-O-methyltransferase gene expression is associated with response to citalopram in obsessive-compulsive disorder Int J Psychiatry Clin Pract 16 2012 277 283
380. D.J. Walther, J.U. Peter, S. Bashammakh, H. Hortnagl, M. Voits, and H. Fink et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform Science 299 2003 76 (Pubitemid 36042402)
381. J.H. Wang, Z.Q. Liu, W. Wang, X.P. Chen, Y. Shu, and N. He et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19 Clin Pharmacol Ther 70 2001 42 47 (Pubitemid 32678801)
382. H.C. Wang, T.L. Yeh, H.H. Chang, P.W. Gean, M.H. Chi, and Y.K. Yang et al. TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients Psychopharmacology (Berl) 213 2011 773 779
383. D. Warden, A.J. Rush, M.H. Trivedi, M. Fava, and S.R. Wisniewski The STAR*D project results: a comprehensive review of findings Curr Psychiatry Rep 9 2007 449 459 (Pubitemid 350284935)
384. J.L. Warner-Schmidt, M. Flajolet, A. Maller, E.Y. Chen, H. Qi, and P. Svenningsson et al. Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation J Neurosci 29 2009 1937 1946
385. N.V. Weisstaub, M. Zhou, A. Lira, E. Lambe, J. Gonzalez-Maeso, and J.P. Hornung et al. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice Science 313 2006 536 540 (Pubitemid 44148461)
386. A. Wesolowska Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data Pharmacol Rep 62 2010 564 577
387. E.M. Whyte, M. Romkes, B.H. Mulsant, M.A. Kirshne, A.E. Begley, and C.F. Reynolds III et al. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly Int J Geriatr Psychiatry 21 2006 542 549 (Pubitemid 44043755)
388. M. Willeit, J. Stastny, W. Pirker, N. Praschak-Rieder, A. Neumeister, and S. Asenbaum et al. No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism Biol Psychiatry 50 2001 8 12 (Pubitemid 32701988)
389. K. Wimalasena Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry Med Res Rev 31 2011 483 519
390. J.G. Wood, P.R. Joyce, A.L. Miller, R.T. Mulder, and M.A. Kennedy A polymorphism in the dopamine beta-hydroxylase gene is associated with "paranoid ideation" in patients with major depression Biol Psychiatry 51 2002 365 369 (Pubitemid 34251173)
391. W.H. Wu, S.J. Huo, C.Y. Cheng, C.J. Hong, and S.J. Tsai Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders Neuropsychobiology 44 2001 172 175
392. Y. Xu, H. Liu, F. Li, N. Sun, Y. Ren, and Z. Liu et al. A polymorphism in the microRNA-30e precursor associated with major depressive disorder risk and P300 waveform J Affect Disord 127 2010 332 336
393. Z. Xu, Z. Zhang, Y. Shi, M. Pu, Y. Yuan, and X. Zhang et al. Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response J Affect Disord 133 2011 165 173
394. Z. Xu, Z. Zhang, Y. Shi, M. Pu, Y. Yuan, and X. Zhang et al. Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response J Psychopharmacol 26 2012 349 359
395. M. Yamazaki, W.E. Neway, T. Ohe, I.W. Chen, J.F. Rowe, and J.H. Hochman et al. In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results J Pharmacol Exp Ther 296 2001 723 735 (Pubitemid 32187340)
396. O.Q. Yin, Y.K. Wing, Y. Cheung, Z.J. Wang, S.L. Lam, and H.F. Chiu et al. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients J Clin Psychopharmacol 26 2006 367 372 (Pubitemid 44192092)
397. Y.R. Yoon, I.J. Cha, J.H. Shon, K.A. Kim, Y.N. Cha, and I.J. Jang et al. Relationship of paroxetine disposition to metroprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects Clin Pharmacol Ther 67 2000 567 576
398. K. Yoshida, S. Naito, H. Takahashi, K. Sato, K. Ito, and M. Kamata et al. Monoamine oxidase: a gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder Prog Neuropsychopharmacol Biol Psychiatry 26 2002 1279 1283 (Pubitemid 35341578)
399. K. Yoshida, H. Takahashi, H. Higuchi, M. Kamata, K. Ito, and K. Sato et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms Am J Psychiatry 161 2004 1575 1580 (Pubitemid 39201453)
400. K. Yoshida, H. Higuchi, M. Kamata, H. Takahashi, K. Inoue, and T. Suzuki et al. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine J Psychopharmacol 21 2007 650 656 (Pubitemid 47472727)
401. K. Yoshida, H. Higuchi, H. Takahashi, M. Kamata, K. Sato, and K. Inoue et al. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran Hum Psychopharmacol 23 2008 121 128 (Pubitemid 351359584)
402. R. Yoshimura, T. Kishi, A. Suzuki, W. Umene-Nakano, A. Ikenouchi-Sugita, and H. Hori et al. The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients Prog Neuropsychopharmacol Biol Psychiatry 35 2011 1022 1025
403. R. Yoshimura, T. Kishi, H. Hori, A. Ikenouchi-Sugita, W. Umene-Nakano, and A. Katsuki et al. No association between the response to the addition of an atypical antipsychotic drug to an SSRI or SNRI and the BDNF (Val66Met) polymorphism in refractory major depressive disorder in Japanese patients Clin Psychopharmacol Neurosci 10 2012 49 53
404. M.B. Youdim, and M. Weinstock Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation Neurotoxicology 25 2004 243 250 (Pubitemid 38044185)
405. Y.W. Yu, S.J. Tsai, T.J. Chen, C.H. Lin, and C.J. Hong Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders Mol Psychiatry 7 2002 1115 1119 (Pubitemid 36044271)
406. B.N. Yu, G.L. Chen, N. He, D.S. Ouyang, X.P. Chen, and Z.Q. Liu et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19 Drug Metab Dispos 31 2003 1255 1259 (Pubitemid 37152977)
407. Y.W. Yu, S.J. Tsai, C.J. Hong, T.J. Chen, M.C. Chen, and C.W. Yang Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response Neuropsychopharmacology 30 2005 1719 1723 (Pubitemid 43086029)
408. Y.W. Yu, S.J. Tsai, Y.J. Liou, C.J. Hong, and T.J. Chen Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders Eur Neuropsychopharmacol 16 2006 498 503 (Pubitemid 44376554)
409. H. Yu, D.D. Wang, Y. Wang, T. Liu, F.S. Lee, and Z.Y. Chen Variant brain-derived neurotrophic factor Val66Met polymorphism alters vulnerability to stress and response to antidepressants J Neurosci 32 2012 4092 4101
410. R. Zanardi, L. Magri, D. Rossini, A. Malaguti, S. Giordani, and C. Lorenzi et al. Role of serotonergic gene polymorphisms on response to transcranial magnetic stimulation in depression Eur Neuropsychopharmacol 17 2007 651 657 (Pubitemid 47268754)
411. C.A. Zarate Jr., J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, and D.A. Luckenbaugh et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch Gen Psychiatry 63 2006 856 864 (Pubitemid 44188478)
412. X. Zhang, J.M. Beaulieu, T.D. Sotnikova, R.R. Gainetdinov, and M.G. Caron Tryptophan hydroxylase-2 controls brain serotonin synthesis Science 305 2004 217 (Pubitemid 38886729)
413. X. Zhang, R.R. Gainetdinov, J.M. Beaulieu, T.D. Sotnikova, L.H. Burch, and R.B. Williams et al. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression Neuron 45 2005 11 16 (Pubitemid 40075345)
414. L. Zhang, Y. Fang, Z. Zeng, Y. Lian, J. Wei, and H. Zhu et al. BDNF gene polymorphisms are associated with Alzheimer's disease-related depression and antidepressant response J Alzheimers Dis 26 2011 523 530
415. Z. Zhou, E.J. Peters, S.P. Hamilton, F. McMahon, C. Thomas, and P.J. McGrath et al. Response to Zhang et al. (2005): loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression Neuron 45 2005 11 16 [Neuron. 2005; 48:702-3; author reply 5-6]
416. R. Zhou, P. Yuan, Y. Wang, J.G. Hunsberger, A. Elkahloun, and Y. Wei et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers Neuropsychopharmacology 34 2009 1395 1405
417. P. Zill, A. Buttner, W. Eisenmenger, H.J. Moller, M. Ackenheil, and B. Bondy Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: a post-mortem study J Psychiatr Res 41 2007 168 173 (Pubitemid 44708201)
418. Y.F. Zou, Y. Wang, P. Liu, X.L. Feng, B.Y. Wang, and T.H. Zang et al. Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients Neuropsychobiology 61 2010 71 78
419. Y.F. Zou, D.Q. Ye, X.L. Feng, H. Su, F.M. Pan, and F.F. Liao Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder Eur Neuropsychopharmacol 20 2010 535 544